Skip to Content
Advertisement
800-533-8762
  • Careers
  • Newsroom
  • Health Care Professionals
  • About Us
  • Contact Us
UPMC
  • Find a Doctor
  • Conditions
  • Services
    • Frequently Searched Services
    • Frequently Searched Services
      Allergy & Immunology Behavioral & Mental Health Cancer Ear, Nose & Throat Endocrinology Gastroenterology Heart & Vascular Imaging Neurosciences Orthopaedics
      Physical Rehabilitation Plastic & Reconstructive Surgery Primary Care Senior Services Sports Medicine Telemedicine Transplant Surgery Walk-In Care Weight Management Women’s Health
      See all Services
    • Services by Region
    • Find a UPMC health care facility close to you quickly by browsing by region.
      UPMC in Western Pa. Western Pa. and New York
      Highlighted Regional Map of UPMC in Central Pa. Central Pa.
      UPMC in North Central Pa. North Central Pa.
      UPMC in Western Md. Maryland & West Virginia
    • See All Services
  • Locations
    • Locations by Type
    • Locations by Type
      UPMC hospitals
      Hospitals
      Physical Therapy
      Physical Therapy
      Urgent care
      Walk-In Care
      UPMC Outpatient Centers
      Outpatient Centers
      UPMC Imaging Services
      Imaging
      Community Health Centers
      Community Health Centers
      See All Locations
    • Locations by Region
    • Locations by Region
      UPMC in Southwest Pa. Southwest Pa.
      UPMC in North Central Pa. North Central Pa.
      UPMC in Northwest Pa and Ny. Northwest Pa. & Western N.Y.
      UPMC in West Central Pa. West Central Pa.
      Highlighted Regional Map of UPMC in Central Pa. Central Pa.
      UPMC in Western Md. Maryland & West Virginia
    • See All Locations
  • Patients & Visitors
    • Patient & Visitor Resources
    • Patient & Visitor Resources
      Patients and Visitors Resources Pay a Bill Classes & Events Health Library International Traveling Patients Medical Records
      Patient Information Patient Portals Privacy Information Shared Decision Making Visitor Information
      Man uses mobile phone
      Pay a Bill
      Nurse reviews medical chart
      Request Medical Records
  • MyUPMC
    • MyUPMC
    • MyUPMC

      Log in to MyUPMC About MyUPMC Proxy & Adolescent Access FAQs
    • Other Patient Portals
    • Other Patient Portals

      UPMC-GoHealth Urgent Care Portal myWHS My Trinity Health Portal
  • Log in to MyUPMC
  • Schedule an appointment
  • Request medical records
  • Pay a bill
  • Learn about financial assistance
  • Find classes & events
  • Send a patient an eCard
  • Make a donation
  • Volunteer
  • Read UPMC HealthBeat
  • Explore UPMC Careers
Skip to Content
UPMC
  • Find a Doctor
    • Doctor Search
  • Conditions
    • Search Conditions We Treat
  • Services
    • Frequently Searched Services
      • Heart and Vascular Services
      • Neurosciences Services
      • Orthopaedics Services
      • Primary Care Services
      • Spine Care Services
      • Sports Medicine Services
      • Transplant Services
      • Women's Health Services
      • See all Services
    • Services by Region
      • Find Care in Western Pa
      • Find Care in Central Pa
      • Find Care in North Central Pa
      • Find Care in Western Maryland
    • See All Services
  • Locations
    • Locations by Type
      • Hospitals
      • Walk-In Care
      • Imaging
      • Physical Therapy
      • Outpatient
      • Community Health Centers
      • See All Locations
    • Locations by Region
      • Central Pa.
      • Maryland and West Virginia
      • North Central Pa.
      • Northwest Pa. & Western N.Y.
      • Southwest Pa.
      • West Central Pa.
    • See All Locations
  • Patients & Visitors
    • MyUPMC
    • More Patient & Visitor Resources
      • Pay a Bill
      • Classes & Events
      • Health Library
      • International Traveling Patients
      • Medical Records
      • Patient Information
      • Privacy Information
      • Shared Decision Making
      • Visitor Information
      • View All Patients and Visitors Resources
  • MyUPMC
    • MyUPMC
      • Log in to MyUPMC
      • About MyUPMC
      • FAQs
      • Proxy & Adolescent Access
    • Other Patient Portals
      • UPMC GoHealth Urgent Care Portal
      • myWHS
      • My Trinity Health Portal
  • I Want To
    • Log in to MyUPMC
    • Schedule an appointment
    • Request medical records
    • Pay a bill
    • Learn about financial assistance
    • Find classes & events
    • Send a patient an eCard
    • Make a donation
    • Volunteer
    • Read UPMC HealthBeat
    • Explore UPMC Careers
  • Careers
  • Contact Us
  • Newsroom
  • UPMC >
  • Media Relations >
  • News Releases >
  • Melanoma protein patterns predict immunotherapy response, studies find
Media Relations
News Releases
Central Pa. News
North Central Pa. News
Contact Us
Experts
Community-Focused News
Media Kits
Media RSS
Media Relations
News Releases
Central Pa. News
North Central Pa. News
Contact Us
Experts
Community-Focused News
Media Kits
Media RSS

Melanoma protein patterns predict immunotherapy response, studies find

For Journalists

Aisha Abdullah
Manager, Science Writing
412-930-1438
abdullaha3@upmc.edu

Allison Hydzik
Director, Science and Research
412-647-9975
hydzikam@upmc.edu

Want to Make an Appointment or Need Patient Information?
Contact UPMC at

1-800-533-8762.

Go to Find a Doctor to search for a UPMC doctor.

Pitt HS Hillman Joint Logo 2026

11/17/2026

Two University of Pittsburgh studies show protein patterns in melanoma tumors can forecast response to immunotherapy and reveal new drug targets. 

PITTSBURGH — Protein patterns in melanoma tumors can predict how patients respond to immunotherapy and can be used to find promising biomarkers and drug targets, according to two University of Pittsburgh studies published Nov. 17, 2026, in the journals Cancer Discovery and Clinical Cancer Research. 

Key Takeaways 

  • Two studies co-led by the University of Pittsburgh investigated protein patterns in melanoma tumors to predict response to immunotherapy and identify potential therapeutic targets. 

  • The Cancer Discovery study analyzed pre-treatment tumors from 183 melanoma patients across 13 molecular levels, creating a comprehensive protein atlas and identifying hundreds of potential drug targets. 

  • The Clinical Cancer Research study analyzed 208 pre-immunotherapy tumor samples, identifying three protein-based tumor subtypes linked to treatment response and survival. 

  • Researchers trained and independently validated a classifier model that uses protein patterns to predict immunotherapy response type and progression-free survival. 

  • Researchers say with further validation the findings could become a clinical assay to guide treatment selection. 

Immune checkpoint inhibitors, a type of cancer immunotherapy, have improved survival for melanoma patients over the past 15 years. Many patients do not respond, and doctors have lacked reliable ways to predict who will benefit before treatment begins. 

To find answers, researchers studied the proteome—the complete set of proteins made by cells in a tissue. Protein patterns, known as predictive biomarkers, can show in advance whether a tumor is likely to respond to a given treatment. 

"In 2003, we decoded the human genome. However, because proteins are the actual molecular machines that carry out the work of life, characterizing the proteomic states of tumors is critical to both understanding both the biology of tumors and identifying prognostic biomarkers," says co-senior author Diwakar Davar, M.D., associate professor at medicine at Pitt and co-leader of the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. "Protein atlases bridge the gap between genomic possibility and therapeutic reality." 

Molecular atlas of melanoma tumors maps protein patterns tied to survival 

The Cancer Discovery study examined pre-treatment tumors from 183 patients with melanoma. Researchers analyzed 13 molecular levels at once, including the genome, proteome and metabolome (the full set of metabolites in a tissue). 

This multi-omics approach produced a molecular atlas of the melanoma tumor microenvironment. The atlas identifies chemical alterations to proteins linked to patient survival, along with hundreds of potential targets for future drugs. 

"To understand the proteomic landscape in melanoma, we needed two different sets of analyses," says Davar. "The primary tumor analysis linked changes in the genome to their protein consequences, revealing therapeutic vulnerabilities and protein patterns in untreated melanoma tumors. The characterization of melanoma tumors before combination immunotherapy revealed the tumor and immune properties that shape sensitivity or resistance to the treatment." 

Three protein-based tumor subtypes predict immunotherapy response  

The Clinical Cancer Research study analyzed 208 tumor samples collected before immunotherapy. The samples came from an international collaboration involving all National Cancer Institute-funded Specialized Program of Research Excellence, or SPORE, programs for melanoma. 

Researchers identified three tumor subtypes based on distinct protein patterns: 

  • An immune-rich group with increased immune activity 

  • A proliferative group with elevated features of cell growth 

  • A growth and metastasis group with characteristics tied to tumor spread 

Each subtype was linked differently to treatment response. The immune-rich group responded best. Among patients who received combination immunotherapy, the subtypes also predicted disease progression and survival. 

Classifier model predicts treatment response, survival across patient groups 

Researchers trained a classifier model to sort tumors into one of the three groups based on protein patterns. The model was independently validated in two separate patient groups. It predicted treatment response type and progression-free survival with a high degree of certainty. 

"We currently lack robust biomarkers to predict which patients will derive benefit from combination immunotherapy. A proteomic biomarker could identify tumors most likely to respond, providing the foundation for a clinical assay to guide treatment selection," said Davar. "Once translated into a validated clinical assay, the biomarker could allow pathology laboratories across the country, from Pittsburgh to Palm Beach, to help determine whether a patient is likely to benefit from treatment." 

Further validation is needed before the findings can be used in clinics. Together, the two studies provide a molecular atlas and a tested classification method that could guide more personalized immunotherapy for melanoma patients. 

Frequently Asked Questions 

Q: What are predictive biomarkers and why do they matter for melanoma immunotherapy?  
A: Predictive biomarkers are measurable features—in this case, protein patterns—that show in advance whether a tumor is likely to respond to treatment. Identifying them could help patients avoid side effects from treatments unlikely to work and start more effective options sooner. 

Q: How many patients were included in the two studies?  
A: The Cancer Discovery study analyzed pre-treatment tumors from 183 melanoma patients. The Clinical Cancer Research study analyzed 208 tumor samples collected before immunotherapy through an international collaboration.  

Q: Is a protein-based biomarker test available to patients now?  
A: Not yet. The researchers said further validation is needed before the findings could be developed into a clinical assay that pathology laboratories could use to guide treatment decisions. 

Additional Resources 

  • A comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas decodes immunogenicity in cutaneous melanoma | Cancer Discovery 

  • Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma | Clinical Cancer Research 

  • Melanoma protein patterns help predict immunotherapy response, survival | EurekAlert! 

  • Melanoma & Skin Cancer | UPMC Hillman Cancer Center  

  • Immunotherapy for Melanoma | UPMC Hillman Cancer Center 

Authors and Funding 

Authors: Pei Wang, Ph.D., of Icahn School of Medicine, Amanda Paulovich, M.D., Ph.D., of at Fred Hutchinson Cancer Center, Marcin Cieslik, Ph.D., of University of Michigan, and Tao Liu, Ph.D., of Pacific Northwest National Laboratory are the co-senior and co-corresponding authors of current studies. 

Funding and Disclosures: This research received support from the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (U24CA270823, U24CA271079, U24CA271012, U24CA271075, U24CA271076, U24CA271037, U24CA271114, U01CA271412, U01CA271410, U01CA271407, U01CA271402), National Institutes of Health (75N91019D00024, 75N91020F00030), National Cancer Institute (P30 CA015704, R50 CA211499, P50 CA225450, U54 CA263001, P50 CA121974), National Center for Advancing Translational Sciences (UL1TR004419), NIH Office of Research Infrastructure Programs (S10OD026880, S10OD030463, S10OD030225, S10OD028685), National Health and Medical Research Council of Australia (2022/GNT2018514), NIH Specialized Program of Research Excellence (SPORE) Melanoma Grant (P50 CA93459), and the Aven Foundation. 

UPMC
200 Lothrop Street Pittsburgh, PA 15213

412-647-8762 800-533-8762

Patients And Visitors
  • Find a Doctor
  • Locations
  • Pay a Bill
  • Patient & Visitor Resources
  • Disabilities Resource Center
  • Services
  • Medical Records
  • No Surprises Act
  • Price Transparency
  • Financial Assistance
  • Classes & Events
  • Health Library
Health Care Professionals
  • Physician Information
  • Resources
  • Education & Training
  • Departments
  • Credentialing
Newsroom
  • Newsroom Home
  • Inside Life Changing Medicine Blog
  • News Releases
About
  • Why UPMC
  • Facts & Stats
  • Supply Chain Management
  • Community Commitment
  • Financials
  • Supporting UPMC
  • UPMC HealthBeat
  • UPMC Apps
  • UPMC Enterprises
  • UPMC Health Plan
  • UPMC International
  • Nondiscrimination Policy
Life changing is...
Follow UPMC
  • Contact Us
  • Website/Email Terms of Use
  • Medical Advice Disclaimer
  • Privacy Information
  • Active Privacy Alerts
  • Sitemap
© 2026 UPMC I Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by WebMD Ignite. To learn more, visit webmdignite.com.
Find Care
Providers
Video Visit
MyUPMC Login

Helpful Prompts

  • cancel: Stops your conversation
  • help: Shows what this bot can do
  • terms: Shows terms of use and privacy statement
  • feedback: Give us feedback
Continue
UPMC
Restart Chat
Chat Help